EDUARD TEIXIDOR VILA

Projectes

Metabolismo y Cáncer

Ayuda de personal Río Hortega 2022 - Eduard Teixidor

Codi oficial: CM22/00276 Data inicio:01/01/2023 Data fi: 31/12/2024 Investigador/a principal: JAVIER ABEL MENÉNDEZ MENÉNDEZ Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

Metabolismo y Cáncer , Oncología de Precisión de Girona

Verdura S, Encinar JA, Gratchev A, Llop-Hernández À, López J, Serrano-Hervás E, Teixidor E, López-Bonet E, Martin-Castillo B, Micol V, Bosch-Barrera J, Cuyàs E, Menendez JA

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Phytomedicine, 2024, 128, 155493-155493 dx.doi.org/10.1016/j.phymed.2024.155493

Oncología de Precisión de Girona , Enfermedades Digestivas y Microbiota

Sabaté-Ortega, J, Albert-Carrasco, M, Escribano-Ferrer, C, Grau-Manrubia, G, Fina-Planas, C, López-Núnez, C, Teixidor-Vilà, E, Bujons-Buscarons, E, Montañés-Ferrer, C, Sala-González, N

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Frontiers in oncology, 2024, 14 dx.doi.org/10.3389/fonc.2024.1354127

Oncología de Precisión de Girona , Metabolismo y Cáncer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Metabolismo y Cáncer , Epidemiología descriptiva, genética y prevención del cáncer , Oncología de Precisión de Girona

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Metabolismo y Cáncer , Oncología de Precisión de Girona

Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N, RENACER, Valiente M

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8

Oncología de Precisión de Girona , Metabolismo y Cáncer

Verdura S, Encinar JA, Teixidor E, Segura-Carretero A, Micol V, Cuyàs E, Bosch-Barrera J, Menendez JA

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14246101

Metabolismo y Cáncer , Oncología de Precisión de Girona

Teixidor E, Bosch-Barrera J

The dark side of immunotherapy: challenges facing the new hope in cancer treatment

Annals of Translational Medicine, 2019, 7 dx.doi.org/10.21037/atm.2019.07.69

Metabolismo y Cáncer , Epidemiología descriptiva, genética y prevención del cáncer , Oncología de Precisión de Girona

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2018, 9, 33043-33049 dx.doi.org/10.18632/oncotarget.25984

Directori

Projectes

Publicacions

Silibinin is a suppressor of the metastasis-promoting transcription factor ID3

Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors

The dark side of immunotherapy: challenges facing the new hope in cancer treatment

Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Formulari de contacte

Conoce el IDIBGI!